Santhera Pharmaceuticals Holding AG (SANN) — Cash Flow Reinvestment Rate

Latest as of December 2023: 0.00x

Santhera Pharmaceuticals Holding AG (SANN) has a Cash Flow Reinvestment Rate of 0.00x as of December 2023, reinvesting CHF90.00K (capex CHF90.00K ) from operating cash flow of CHF62.63 Million. See cash generation quality of Santhera Pharmaceuticals Holding AG to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.00x

(Capex + Investments) / Operating CF

Total Reinvested

CHF90.00K

Capex + Investments

Operating Cash Flow

CHF62.63 Million

CHF

Capital Expenditures

CHF90.00K

CHF

Santhera Pharmaceuticals Holding AG Cash Flow Reinvestment Rate (2019–2023)

Historical reinvestment intensity for Santhera Pharmaceuticals Holding AG across 2 annual periods. For the full cash flow conversion analysis, see Santhera Pharmaceuticals Holding AG cash flow conversion.

Annual Cash Flow Reinvestment Rate for Santhera Pharmaceuticals Holding AG (2019–2023)

Year-by-year capital reinvestment analysis for Santhera Pharmaceuticals Holding AG. See Santhera Pharmaceuticals Holding AG free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (CHF)	Operating CF	Capex	YoY Change
2023	0.88x	CHF41.79 Million	CHF47.27 Million	CHF23.74 Million	▲ +828.7%
2019	0.10x	CHF247.00K	CHF2.60 Million	CHF229.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow